Sickle cell anemia does not only affect African Americans. It is most common in people of African descent, but it also occurs in people of Mediterranean, Middle Eastern, and Indian heritage. The reason it’s concentrated in these populations has nothing to do with race itself. It comes down to geography, specifically where malaria has historically been most deadly.
In the United States, the disease occurs in about 1 out of every 365 Black or African American births and about 1 out of every 16,300 Hispanic American births. Roughly 100,000 Americans live with sickle cell disease. Because the majority of affected people in the U.S. are Black, a common misconception developed that the disease is exclusive to African Americans.
The Malaria Connection
The sickle cell gene persists in certain populations because carrying one copy of it provides a powerful survival advantage against malaria. Malaria, caused by a parasite transmitted through mosquito bites, has killed more humans throughout history than almost any other infectious disease. It thrives in tropical and subtropical regions: sub-Saharan Africa, the Mediterranean coast, the Arabian Peninsula, and parts of India.
In these regions, people who carried a single copy of the sickle cell gene (called sickle cell trait) were more likely to survive malaria and live long enough to have children. Over thousands of years, natural selection kept the gene circulating at high frequencies in these populations. Research published in the Proceedings of the National Academy of Sciences showed exactly how this works at the cellular level: when the malaria parasite infects a red blood cell that contains sickle hemoglobin, the altered hemoglobin stiffens and polymerizes in low-oxygen environments. This stalls the parasite’s growth before it can replicate its DNA, dramatically reducing the number of parasites in the bloodstream.
This protection is partial, not absolute, but it was enough to make a life-or-death difference in regions where malaria was a constant threat. People without the gene died of malaria at higher rates. People with two copies of the gene developed sickle cell disease and often died young. But people with exactly one copy got the best of both worlds: malaria resistance without the full disease. This is a textbook example of what biologists call a “balanced polymorphism,” where a gene that’s harmful in double dose is kept alive in the population because a single dose is beneficial.
Where the Gene Actually Exists
The sickle cell gene is not tied to skin color or racial categories. It tracks with geography and ancestry from malaria-endemic regions. In parts of sub-Saharan Africa, as many as 25% of the population carries sickle cell trait. But the gene is also found at significant rates in other groups:
- India: Among certain tribal populations, the rate of sickle cell trait reaches as high as 40%. Research from the American Society of Hematology traced the gene’s presence in India to a migration event roughly 50,000 years ago, when early humans traveled from Africa through the Arabian Peninsula along the eastern coastal route.
- Mediterranean region: People of Greek, Italian (particularly Sicilian and Sardinian), and Turkish descent carry the gene at elevated rates, corresponding to areas where malaria was endemic for centuries.
- Middle East: Populations across Saudi Arabia, Oman, and other Gulf states have well-documented rates of sickle cell disease and trait.
- Hispanic and Latino populations: People with ancestry from the Caribbean, Central America, and South America can carry the gene, reflecting both African and Indigenous genetic heritage from malaria-prone regions.
In India, many of the tribal communities that carry the gene have practiced endogamy (marriage within the community) for generations. This kept the gene concentrated within those groups rather than spreading into the broader Indian population, which is why sickle cell disease in India is heavily clustered in specific tribal populations rather than evenly distributed.
How Sickle Cell Disease Is Inherited
Sickle cell disease is caused by a single change in the gene that codes for hemoglobin, the protein in red blood cells that carries oxygen. One amino acid in the hemoglobin chain is swapped out for a different one. That tiny substitution causes hemoglobin molecules to clump together under low-oxygen conditions, distorting red blood cells into a rigid, crescent shape instead of their normal flexible disc.
The disease follows an autosomal recessive pattern, meaning a child must inherit the altered gene from both parents to develop the full disease. If both parents carry sickle cell trait (one normal copy and one sickle copy), each pregnancy has a 25% chance of producing a child with sickle cell disease, a 50% chance of producing a child with sickle cell trait, and a 25% chance of producing a child with two normal copies. These odds reset with every pregnancy.
About 1 in 13 Black or African American babies is born with sickle cell trait. Most of these individuals never develop symptoms. They can, however, pass the gene to their children.
Why It Seems Like a “Black Disease” in the U.S.
The perception that sickle cell anemia is exclusively an African American disease is largely an artifact of American demographics and medical history. The transatlantic slave trade forcibly brought millions of West and Central Africans to the Americas, and these populations came from regions with some of the highest rates of sickle cell trait in the world. As a result, African Americans inherited the gene at much higher frequencies than other American ethnic groups.
Early medical research in the U.S. reinforced this association. When sickle cell disease was first studied in depth in the mid-20th century, nearly all identified patients were Black. Screening programs initially targeted African American communities. Since May 2006, all U.S. states have required universal newborn screening for sickle cell disease, meaning every baby born in the country is tested regardless of race or ethnicity. This has helped identify cases in non-Black populations that might previously have been missed or misdiagnosed.
Globally, sickle cell disease is not a rare condition. It affects millions of people across Africa, India, the Middle East, and the Mediterranean. Framing it as an African American disease obscures the true scope of the problem and can lead to delayed diagnosis in affected individuals who don’t fit the expected racial profile. A child of Greek or Saudi Arabian descent with unexplained pain crises and anemia deserves the same diagnostic consideration as an African American child with identical symptoms.
A 50,000-Year-Old Survival Strategy
Research tracing the origins of the sickle cell mutation suggests it arose in Africa roughly 50,000 years ago and spread as early humans migrated outward. The gene traveled along established migration routes, through the Arabian Peninsula and into India, and later spread through the Mediterranean through trade, conquest, and population mixing over millennia. Everywhere it went, it followed malaria.
This is why the global map of sickle cell trait prevalence overlaps almost perfectly with the historical map of malaria transmission. The gene is not a marker of race. It is a marker of ancestral exposure to one of humanity’s oldest and deadliest diseases. In populations where malaria was never a significant threat, such as Northern Europeans or East Asians, the sickle cell gene provides no survival benefit and therefore never became common.